BR112022008641A2 - Métodos de tratamento com modulador de miosina - Google Patents

Métodos de tratamento com modulador de miosina

Info

Publication number
BR112022008641A2
BR112022008641A2 BR112022008641A BR112022008641A BR112022008641A2 BR 112022008641 A2 BR112022008641 A2 BR 112022008641A2 BR 112022008641 A BR112022008641 A BR 112022008641A BR 112022008641 A BR112022008641 A BR 112022008641A BR 112022008641 A2 BR112022008641 A2 BR 112022008641A2
Authority
BR
Brazil
Prior art keywords
myosin
methods
treatment
modulator
mavacantene
Prior art date
Application number
BR112022008641A
Other languages
English (en)
Portuguese (pt)
Inventor
Carlson Timothy
L Del Rio Carlos
M Edelberg Jay
Fernandes Sarah
Patrick Henze Marcus
Yanfei Ma Grace
Mcdowell Robert
Edwards Mealiffe Matthew
Sehnert Amy
J Semigran Marc
L Lampl Kathy
Zhang David
Y Desai Milind
Nissen Steve
Fang Liang
Li Wanying
Lambing Joseph
Edmund Kane Brian
L Aubele Danielle
Charles Sehl Louis
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of BR112022008641A2 publication Critical patent/BR112022008641A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022008641A 2019-11-10 2020-11-10 Métodos de tratamento com modulador de miosina BR112022008641A2 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US202063064450P 2020-08-12 2020-08-12
PCT/US2020/059893 WO2021092598A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
BR112022008641A2 true BR112022008641A2 (pt) 2022-09-13

Family

ID=75849342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008641A BR112022008641A2 (pt) 2019-11-10 2020-11-10 Métodos de tratamento com modulador de miosina

Country Status (13)

Country Link
US (1) US20230158027A1 (https=)
EP (1) EP4054588A4 (https=)
JP (1) JP7830321B2 (https=)
KR (1) KR20220113387A (https=)
CN (1) CN114945372A (https=)
AU (1) AU2020378197A1 (https=)
BR (1) BR112022008641A2 (https=)
CA (1) CA3157629A1 (https=)
CL (1) CL2022001217A1 (https=)
IL (1) IL292840A (https=)
MX (1) MX2022005465A (https=)
TW (1) TW202134259A (https=)
WO (1) WO2021092598A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
HUE069154T2 (hu) * 2020-01-28 2025-02-28 Assia Chem Ind Ltd A mavakamten szilárd állapotú formái és eljárás elõállításukra
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PT4370116T (pt) * 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
CA3248508A1 (en) 2022-04-13 2023-10-19 Assia Chemical Industries Ltd. SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD
EP4514355A1 (en) * 2022-04-26 2025-03-05 MyoKardia, Inc. Methods of administering myosin inhibitors
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
WO2025096779A2 (en) * 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
EP3399907A4 (en) * 2016-01-04 2019-08-28 Aventusoft, LLC SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS
CA3071948A1 (en) * 2017-08-04 2019-02-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Also Published As

Publication number Publication date
MX2022005465A (es) 2022-08-08
EP4054588A1 (en) 2022-09-14
CA3157629A1 (en) 2021-05-14
TW202134259A (zh) 2021-09-16
AU2020378197A1 (en) 2022-05-26
KR20220113387A (ko) 2022-08-12
CL2022001217A1 (es) 2023-01-13
WO2021092598A1 (en) 2021-05-14
US20230158027A1 (en) 2023-05-25
JP2023501453A (ja) 2023-01-18
CN114945372A (zh) 2022-08-26
IL292840A (en) 2022-07-01
JP7830321B2 (ja) 2026-03-16
EP4054588A4 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
BR112022008641A2 (pt) Métodos de tratamento com modulador de miosina
MX2024010140A (es) Nuevos metodos.
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112021013415A2 (pt) Proteínas de fusão multifuncionais e usos das mesmas
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112018003870A2 (pt) construções cirúrgicas tubulares incluindo material auxiliar
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
EA202190569A1 (ru) Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
BR112022003762A2 (pt) Proteínas de fusão terapêuticas
MX2021000340A (es) Nuevos compuestos.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2021009384A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
WO2022043273A3 (en) Oral care composition comprising a fructanase

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]